Objective To estimate the incidence of hepatitis C virus (HCV) seroconversion and the risk of severe fibrosis/cirrhosis in HCV seroconverters among persons with human immunodeficiency virus (HIV) infection. Methods We analysed data on 4059 persons with HIV enrolled in a cohort study in Italy. Results Incidence rate of seroconversion was 0.6/100 person-years overall, and drug users and men-who-have-sex-with-men were at highest risk. The cumulative risk of progression to severe fibrosis/cirrhosis was 30% by 10 years after seroconversion. Conclusions New HCV infections have a rapidly progressive course in this population. Persons with HIV and HCV superinfection should be prioritized for treatment with anti-HCV direct-acting antivirals.

Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus / M. Puoti, P. Lorenzini, A. Cozzi-Lepri, A. Gori, C. Mastroianni, G. Rizzardini, G. Mazzarello, A. Antinori, A. d'Arminio Monforte, E. Girardi, M. Andreoni, G. Angarano, A. Antinori, F. Castelli, R. Cauda, G. Di Perri, M. Galli, R. Iardino, G. Ippolito, A. Lazzarin, C.F. Perno, F. von Schloesser, P. Viale, A. Castagna, F. Ceccherini-Silberstein, S. Lo Caputo, C. Mussini, A. Ammassari, C. Balotta, A. Bandera, P. Bonfanti, S. Bonora, M. Borderi, A. Calcagno, L. Calza, M.R. Capobianchi, A. Cingolani, P. Cinque, A. De Luca, A. Di Biagio, N. Gianotti, G. Guaraldi, G. Lapadula, M. Lichtner, G. Madeddu, F. Maggiolo, G. Marchetti, S. Marcotullio, L. Monno, S. Nozza, E. Quiros Roldan, R. Rossotti, S. Rusconi, M.M. Santoro, A. Saracino, M. Zaccarelli, I. Fanti, L. Galli, A. Rodano, M. Shanyinde, A. Tavelli, F. Carletti, S. Carrara, A. Di Caro, S. Graziano, F. Petrone, G. Prota, S. Quartu, S. Truffa, A. Giacometti, A. Costantini, C. Valeriani, C. Santoro, C. Suardi, V. Donati, G. Verucchi, C. Minardi, T. Quirino, C. Abeli, P.E. Manconi, P. Piano, B. Cacopardo, B. Celesia, J. Vecchiet, K. Falasca, L. Sighinolfi, D. Segala, F. Mazzotta, F. Vichi, G. Cassola, C. Viscoli, A. Alessandrini, N. Bobbio, V. Belvisi, I. Caramma, A. Chiodera, A.P. Castelli, A.L. Ridolfo, R. Piolini, S. Salpietro, L. Carenzi, M.C. Moioli, C. Tincati, C. Puzzolante, N. Abrescia, A. Chirianni, G. Borgia, F. Di Martino, L. Maddaloni, I. Gentile, R. Orlando, F. Baldelli, D. Francisci, G. Parruti, T. Ursini, G. Magnani, M.A. Ursitti, V. Vullo, A. Cristaudo, A. Cingolani, S. Cicalini, L. Gallo, E. Nicastri, R. Acinapura, M. Capozzi, R. Libertone, S. Savinelli, A. Latini, G. Iaiani, L. Fontanelli Sulekova, M. Cecchetto, F. Viviani, M.S. Mura, B. Rossetti, P. Caramello, G.C. Orofino, M. Sciandra, M. Bassetti, A. Londero, G. Pellizzer, V. Manfrin, G. Baldin. - In: CLINICAL MICROBIOLOGY AND INFECTION. - ISSN 1198-743X. - 23:4(2017 Apr 01), pp. 267E1-267E4. [10.1016/j.cmi.2016.12.003]

Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus

A. Gori;A. d'Arminio Monforte;M. Galli
Membro del Collaboration Group
;
C.F. Perno
Membro del Collaboration Group
;
C. Balotta
Membro del Collaboration Group
;
A. Bandera
Membro del Collaboration Group
;
G. Marchetti
Membro del Collaboration Group
;
S. Rusconi
Membro del Collaboration Group
;
R. Piolini;L. Carenzi
Membro del Collaboration Group
;
C. Tincati
Membro del Collaboration Group
;
2017

Abstract

Objective To estimate the incidence of hepatitis C virus (HCV) seroconversion and the risk of severe fibrosis/cirrhosis in HCV seroconverters among persons with human immunodeficiency virus (HIV) infection. Methods We analysed data on 4059 persons with HIV enrolled in a cohort study in Italy. Results Incidence rate of seroconversion was 0.6/100 person-years overall, and drug users and men-who-have-sex-with-men were at highest risk. The cumulative risk of progression to severe fibrosis/cirrhosis was 30% by 10 years after seroconversion. Conclusions New HCV infections have a rapidly progressive course in this population. Persons with HIV and HCV superinfection should be prioritized for treatment with anti-HCV direct-acting antivirals.
Cirrhosis; Cohort study; Hepatitis C virus; Human immunodeficiency virus; Incidence; Cohort Studies; Disease Progression; Female; HIV Infections; Hepatitis C; Humans; Incidence; Italy; Kaplan-Meier Estimate; Liver Cirrhosis; Male; Population Surveillance; Risk; Coinfection; Microbiology (medical); Infectious Diseases
Settore MED/07 - Microbiologia e Microbiologia Clinica
1-apr-2017
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1198743X16306085-main.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 278.92 kB
Formato Adobe PDF
278.92 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/623245
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 7
social impact